In this randomized trial including 330 pts with MPE, talc slurry and VATS talc insufflation under local anesthesia had similar failure rates (24% vs 22%) at 90 days.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Pleura - Effusion
December 6, 2019
In this multi-institutional randomized trial comparing talc slurry through a chest tube to talc pudrage during VATS, success rates at 90 days were similar.
January 7, 2019
Malignant pleural effusions (MPE) affect up to 15% of all patients with cancer, and in the last few years several well-designed randomized clinical trials have been published.
April 5, 2018
Bhatnagar and colleagues randomized patients with malignant pleural effusion in order to test an outpatient approach to pleurodesis. All patients had indwelling pleural catheters placed for drainage, and they received a daily administration of either talc slurry or placebo through the catheter on an outpatient basis.
January 12, 2018
The authors summarizes a personal experience with 529 patients undergoing VATS operations under local anesthesia and sedation. No nerve block, epidural, laryngeal mask airway, or endotracheal intubation was used. Indications were lung nodule, hemothorax, empyema, pleural effusion, pericardial effusion, chylothorax, etc. There was one unsuccessful
November 6, 2014
The authors performed a single center review to assess outcomes of thoracentesis for inpatients. For 9,320 thoracenteses in 4,618 patients the incidence of adverse outcomes was quite low: pneumothorax 0.6%, reexpansion pulmonary edema 0.01%, and bleeding 0.2%. Current guidelines may not be aligned with outcomes of expert clinical practice.
August 7, 2014
The authors developed and validated a survival predictive score for patients with malignant pleural effusion using 3 large international cohorts of patients. The LENT score is based on LDH level, ECOG performance status, neutrophil to lymphocyte ratio, and tumor type. Low risk patients had a median survival of 319 days, moderate risk group survival
March 15, 2014
The authors evaluated the impact of small (<10mm) pleural effusion on outcomes in patients with NSCLC. Of over 2000 pts, minimal PE was present in 13%. It was more common in patients with more advanced stages. Minimal PE was associated with decreased median survival (7.7 vs 17.7 mos) after adjustment for other prognostic variables. The impact